Filana Therapeutics (MEX:FLNA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


MEX:FLNA Filana Therapeutics Inc MEX:FLNA
33 GF Score
Price MXN27.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Filana Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:FLNA vs XBIT, MCRB, LIXT: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Filana Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Filana Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


MEX:FLNA
33GF Score
Filana Therapeutics Inc MEX:FLNA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
33GF Score

Get the complete analysis for MEX:FLNA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN27.00
Price